Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $2.64 million
- Book Value:
- Revenue TTM:
- $24.92 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Novan Inc had its IPO on 2016-09-21 under the ticker symbol NOVN.
The company operates in the Healthcare sector and Pharmaceuticals industry. Novan Inc has a staff strength of 90 employees.
Shares of Novan Inc opened at $0.02 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.02 - $0.03, and closed at $0.02.
This is a +19.5% increase from the previous day's closing price.
A total volume of 78,866 shares were traded at the close of the day’s session.
In the last one week, shares of Novan Inc have slipped by -46.89%.
Novan Inc's Key Ratios
Novan Inc has a market cap of $2.64 million, indicating a price to book ratio of 5.1023 and a price to sales ratio of 2.2951.
In the last 12-months Novan Inc’s revenue was $24.92 million with a gross profit of $313000 and an EBITDA of $-36206000. The EBITDA ratio measures Novan Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Novan Inc’s operating margin was -159.12% while its return on assets stood at -25.84% with a return of equity of -2098.89%.
In Q1, Novan Inc’s quarterly earnings growth was a negative -61.5% while revenue growth was a positive 64.2%.
Novan Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.84 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Novan Inc’s profitability.
Novan Inc stock is trading at a EV to sales ratio of 1.7064 and a EV to EBITDA ratio of -0.7115. Its price to sales ratio in the trailing 12-months stood at 2.2951.
Novan Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $79.79 million
- Total Liabilities
- $43.91 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Novan Inc ended 2023 with $79.79 million in total assets and $0 in total liabilities. Its intangible assets were valued at $79.79 million while shareholder equity stood at $-2828000.00.
Novan Inc ended 2023 with $0 in deferred long-term liabilities, $43.91 million in other current liabilities, 3000.00 in common stock, $-324399000.00 in retained earnings and $4.06 million in goodwill. Its cash balance stood at $12.54 million and cash and short-term investments were $12.54 million. The company’s total short-term debt was $465,000 while long-term debt stood at $0.
Novan Inc’s total current assets stands at $32.69 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $13.84 million compared to accounts payable of $14.32 million and inventory worth $1.12 million.
In 2023, Novan Inc's operating cash flow was $-23000.00 while its capital expenditure stood at $23000.
Comparatively, Novan Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Novan Inc stock is currently trading at $0.02 per share. It touched a 52-week high of $2.45 and a 52-week low of $2.45. Analysts tracking the stock have a 12-month average target price of $10.8.
Its 50-day moving average was $0.16 and 200-day moving average was $0.96 The short ratio stood at 0.71 indicating a short percent outstanding of 0%.
Around 86.9% of the company’s stock are held by insiders while 1492.7% are held by institutions.
Frequently Asked Questions About Novan Inc
Similar Industry Stocks (Pharmaceuticals)
Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete’s foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina. On July 17, 2023, Novan, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.